Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Interstitial lung disease (ILD) is a serious side effect of certain mBC treatments, but our understanding of its prevalence outside of clinical trials and treatment-specific studies is limited. We sought to characterize the incidence of ILD among a large, population-based cohort of adults with mBC in the United States. METHODS: We included females and males aged 66 + years who were diagnosed with Stage IV breast cancer (as their first cancer) between January 1, 2002-December 31, 2017, using the SEER-Medicare linked. Our primary outcome was an incident ILD diagnosis after their mBC diagnosis, which was operationalized as a binary outcome. We examined demographic and clinical factors associated with incident ILD using logistic regression models. RESULTS: Among the 14,343 patients with mBC and no evidence of ILD at baseline, the median age at diagnosis was 76 (IQR 70, 82) years and 98% were female. Overall, 1,806 (12.6%) had an ILD diagnosis after mBC diagnosis. There was no significant difference in proportion of patients who received a pharmacologic treatment that carries the potential risk of ILD between patients who received an ILD diagnosis and those who did not (14% vs. 12%). CONCLUSIONS: ILD is prevalent in 12.6% of adults with mBC, yet oncology guidelines for monitoring for this intrusive and potentially fatal complication are sparse and non-specific. Patient education raising awareness of ILD symptoms and engaging primary care and pulmonary medicine in may improve patient outcomes and quality of life.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,190
Awards: G1352184354, G1395202410, G2337224928, CALIFORNIA COORDINATED CANCER PREVENTION AND CONTROL PROGRAM; CALFORNIA COMPREHENSIVE CANCER CONTROL PROGRAM; CALIFORNIA CANCER REGISTRY - THE CALIFORNIA DEPARTMENT OF PUBLIC HEALTH (CDPH) HAS CONDUCTED CANCER PREVENTION AND CONTROL ACTIVITIES FUNDED BY THE CENTERS FOR DISEASE CONTROL FOR MORE THAN 35 YEARS. THESE INCLUDE HIGH PERFORMING, NATIONALLY RECOGNIZED PROGRAMS, INCLUDING THE CALIFORNIA CANCER REGISTRY (CCR) AND THE CALIFORNIA COMPREHENSIVE CANCER CONTROL PROGRAM (CCCCP). THESE PROGRAMS SAVE LIVES OF CALIFORNIANS BY PREVENTING AND REDUCING THE DEVASTATING EFFECTS OF CANCER ACROSS THE CANCER CONTROL CONTINUUM (PREVENTION TO SURVIVORSHIP) THROUGH ADVANCING POLICY, EDUCATION, EARLY DETECTION, DIAGNOSIS, TREATMENT, AND SURVIVORSHIP WITH AN INTEGRATED FOCUS ON REDUCING HEALTH DISPARITIES. AT ITS CORE, THE PURPOSE OF CCR IS TO MONITOR THE BURDEN OF CANCER ACROSS THE ENTIRE STATE, ASSIST IN CANCER CONTROL PROGRAM EVALUATION AND GUIDANCE, RESPOND TO PUBLIC CONCERNS ABOUT CANCER, AND PROVIDE HIGH QUALITY STRUCTURED DATA IN SUPPORT OF RESEARCH, PREVENTIVE AND CLINICAL CARE, AND IMPROVING CANCER OUTCOMES FOR ALL SURVIVORS. CCCCP’S OVERARCHING GOALS ARE TO PROVIDE THE INFRASTRUCTURE TO ENSURE COORDINATION OF CANCER CONTROL EFFORTS IN CALIFORNIA, ENGAGEMENT OF ALL CANCER CONTROL CONSTITUENTS THROUGH THE CALIFORNIA DIALOGUE ON CANCER AND DEVELOP OUR STATE’S CANCER CONTROL PLAN TO GUIDE AND EVALUATE OTHER PROGRAMS’ AND STAKEHOLDERS’ ACTIVITIES BASED ON THE LATEST EVIDENCE BASED STRATEGIES. THE TWO PROGRAMS DESCRIBED IN THIS PROPOSAL ARE HIGHLY COMMITTED TO COLLABORATION AMONG THEMSELVES, WITH THE CALIFORNIA EARLY BEAST AND CERVICAL CANCER SCREENING PROGRAM, AS WELL AS OTHER PARTNERS BOTH INSIDE AND OUTSIDE THE STATE. BASED ON THESE PRINCIPLES, THE CCR AND CCCP WILL SUCCESSFULLY APPLY THE CENTERS FOR DISEASE CONTROL AND PREVENTION PROGRAM STANDARDS TO ACHIEVE THE ULTIMATE GOAL OF REDUCING THE CANCER BURDEN OF CALIFORNIA AND THE NATION., G2612351997, G3448447748, G3509688676, G4332884407, G4428815567, G4854421162, G504639888, G6951404960, G7290139498, G8083727551, G8509442309, Cancer Center Support Grant, Multi-level drivers of cardiovascular health during cancer survivorship, G946791773
OpenAlex ID: W7202070032